Kazia Therapeutics released its March 2026 corporate overview and fact sheet, highlighting paxalisib clinical progress in TNBC and GBM, NDL2 development toward IND in 2026, and US$46 million cash runway into 2029.
Key takeaways
Cash and equivalents approximately US$46 million, runway into 2029 excluding additional trials, no outstanding debt.
Paxalisib: complete metabolic response in stage IV TNBC expanded access patient, two partial responses in ongoing Phase 1b metastatic TNBC study.
GBM AGILE Phase 2/3 trial showed clinically meaningful OS improvement in newly diagnosed unmethylated GBM patients.
NDL2 PD-L1 protein degrader: IND initiating studies commencing 2026.
American Depository Shares outstanding: approximately 11.4 million.
Upcoming catalysts include FDA discussion on paxalisib GBM path Q2 2026 and breast cancer study readouts 2H 2026.